 Connection
Bradley Dixon to Adolescent
This is a "connection" page, showing publications Bradley Dixon has written about Adolescent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.209 |
|
|
|
-
Dixon BP, Bomback AS, Rich C, Hakimi Z, Huang M, Gordon K, Wojciechowski P, Margas W, Chang R, Duh MS, Caravaca-Fontán F, Fakhouri F. Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. Adv Ther. 2026 Aug; 43(8):3385-3402.
Score: 0.061
-
Denburg MR, Goodwin Davies AJ, Maltenfort MG, Mitsnefes MM, Flynn JT, Neu AM, Dixon BP, Glenn DA, Gluck CA, Harshman LA, Katsoufis CP, Leonard MB, Modi ZJ, Pan CG, Patel HP, Patterson LT, Verghese PS, Wilson AC, Jovanovska A, Levondosky R, Levondosky M, Dickinson K, Wieand K, Razzaghi H, Li L, Chen Y, Forrest CB. Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatr. 2026 May 01; 180(5):546-555.
Score: 0.015
-
Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 04; 393(22):2210-2220.
Score: 0.015
-
Atkinson MA, Chang JC, Davies AG, Maltenfort M, Luna IY, Scobell R, Mitsnefes M, Stotter BR, Dharnidharka VR, Dixon BP, Flynn JT, Gluck C, Kallash M, Smoyer WE, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Wenderfer SE. Using a multi-institutional pediatric learning health system to characterize induction therapy for incident lupus nephritis in children. Pediatr Nephrol. 2026 Apr; 41(4):1045-1053.
Score: 0.015
-
Denburg MR, Hirabayashi K, Davies AG, Razzaghi H, Dharnidharka VR, Dixon BP, Flynn JT, Gluck CA, Mitsnefes MM, Smoyer WE, Furth SL, Forrest CB. Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022. Pediatr Nephrol. 2025 Oct; 40(10):3121-3127.
Score: 0.014
-
Portale AA, Ward L, Dahir K, Florenzano P, Ing SW, Jan de Beur SM, Martin RM, Meza-Martinez AI, Paloian N, Ashraf A, Dixon BP, Khan A, Langman C, Chen A, Wang C, Roberts MS, Tandon PK, Bedrosian C, Imel EA. Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. J Bone Miner Res. 2024 09 26; 39(10):1493-1502.
Score: 0.014
-
Dharnidharka VR, Scobell RR, Kallash M, Davies AJG, Marchesani N, Maltenfort MG, Walther L, Kelton M, Bock M, Blanchette E, Stone HK, Gluck C, Hullekes F, Riella LV, Smoyer WE, Mitsnefes M, Dixon BP, Flynn JT, Somers MJG, Forrest CB, Furth S, Denburg MR. Clinical characteristics and favorable treatment responses of recurrent focal segmental glomerulosclerosis or steroid-resistant nephrotic syndrome in children after kidney transplantation. Pediatr Nephrol. 2024 Nov; 39(11):3317-3331.
Score: 0.013
-
Stotter BR, Cody E, Gu H, Daga A, Greenbaum LA, Duong MD, Mazo A, Goilav B, Boneparth A, Kallash M, Zeid A, Seeherunvong W, Scobell RR, Alhamoud I, Carter CE, Shah S, Straatmann CE, Dixon BP, Cooper JC, Nelson RD, Levy DM, Brunner HI, Verghese PS, Wenderfer SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatr Nephrol. 2023 05; 38(5):1653-1665.
Score: 0.012
-
Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA. Using a Multi-Institutional Pediatric Learning Health System to Identify Systemic Lupus Erythematosus and Lupus Nephritis: Development and Validation of Computable Phenotypes. Clin J Am Soc Nephrol. 2022 01; 17(1):65-74.
Score: 0.011
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
Score: 0.010
-
Benoit SW, Dixon BP, Goldstein SL, Bennett MR, Lane A, Lounder DT, Rotz SJ, Gloude NJ, Lake KE, Litts B, Davies SM. A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 09; 54(9):1453-1461.
Score: 0.009
-
Siroky BJ, Towbin AJ, Trout AT, Schäfer H, Thamann AR, Agricola KD, Tudor C, Capal J, Dixon BP, Krueger DA, Franz DN. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. J Pediatr. 2017 08; 187:318-322.e2.
Score: 0.008
-
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19; 122(12):2003-7.
Score: 0.006
-
Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar; 10(3):687-91.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|